pOL 3
Homo sapiens
Protocols: Brain tissue was obtained from adults undergoing surgical resections as treatment for non-tumor-related intractable epilepsy in accordance with the guidelines set by the Biomedical Ethics Unit of McGill University. As described (Cui QL, et al. (2010) Response of Human Oligodendrocyte Progenitors to Growth Factors and Axon Signals. J Neuropathol. Exp. Neurol.) tissue specimens were enzymatically digested and placed on a linear 30% Percoll density gradient (Pharmacia Biotech, Piscataway, NJ). Microglia were separated and removed from the specimens by an initial adhesion step in which the total cell fraction was cultured for 24 hours in non-coated flasks. The floating cell fraction (referred to as primary human oligodendrocytes (pOL) was collected, resuspended in 250μl of RLT buffer (Quiagen) and shipped to Münster for RNA extraction. Following total RNA extraction using the RNasy Mini Kit (Quiagen) and DNase (Quiagen) treatment the quality of the produced RNA was tested with Bioanalyzer analysis (Agilent). Samples with RIN value over 7 were used for RNA sequencing. The date of RNA Isolation is 06.09.2018. NEBNext® Poly(A) mRNA Magnetic Isolation Module was followed by a directional library preparation (NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina®). The date of library preparation is 17.09.2018.
ENA-FIRST-PUBLIC
2020-01-31T04:02:42Z
ENA-LAST-UPDATE
2019-04-02T16:09:32Z
External Id
SAMEA5546675
INSDC center name
Max Planck Institute for Molecular Biomedicine
INSDC first public
2020-01-31T04:02:42Z
INSDC last update
2019-04-02T16:09:32Z
INSDC status
public
Submitter Id
E-MTAB-7838:pOL 3
broker name
ArrayExpress
cell type
primary human oligodendrocytes
common name
human
developmental stage
adult
disease
non-tumor-related intractable epilepsy
individual
pOL 3
organism part
brain
progenitor cell type
oligodendrocyte
sample name
E-MTAB-7838:pOL 3
scientific_name
Homo sapiens
sex
male